Ambrosia Biosciences
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $150.0Mattributed |
|---|---|
| Latest round | series-b, $100.0M, 2026-04-01attributed |
| Founded | 2022 |
| Headquarters | Boulder CO |
| Industry | bio |
| Stage | series-b+ |
| Website | ambrosiabiosciences.com |
Drug discovery company developing oral small-molecule therapies for obesity and metabolic disease via GPCR targets. Targets pharma partners and metabolic-disease patients underserved by peptide GLP-1s. Differentiates with structure-based discovery combining cryo-EM, biophysical assays, and AI molecular design.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-01 | series-b | $100.0M | undisclosed |
Detected tech stack
Cloudflare, WordPress 6.9.4, jQuery Migrate 3.4.1, Popper, Cloudflare Bot Management, Vercel Speed Insights, web-vitals, PHP, MySQL, jquery 3.7.1, bootstrap 5.3.2
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $100.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $150.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | ambrosiabiosciences.com, read 2026-05-02 |
| Description | self-reported | ambrosiabiosciences.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.